Dr. Dreicer on Trial Endpoints in Prostate Cancer

Robert Dreicer, MD
Published: Tuesday, Apr 29, 2014

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.

In early disease settings, the trial endpoints that are needed for regulatory approval take longer to achieve, Dreicer says. The ability to hit the survival endpoint in a disease where patients can then subsequently receive other active drug may make the survival endpoint very difficult to reach.

Dreicer believes that survival endpoints will remain difficult to reach in some disease stages until intermediate endpoints are routinely applied in prostate cancer.
 
SELECTED
LANGUAGE
Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.

In early disease settings, the trial endpoints that are needed for regulatory approval take longer to achieve, Dreicer says. The ability to hit the survival endpoint in a disease where patients can then subsequently receive other active drug may make the survival endpoint very difficult to reach.

Dreicer believes that survival endpoints will remain difficult to reach in some disease stages until intermediate endpoints are routinely applied in prostate cancer.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x